NASDAQ:IPXL - Impax Laboratories Stock Price, Price Target & More

$20.50 +0.30 (+1.49 %)
(As of 04/20/2018 10:54 AM ET)
Previous Close$20.20
Today's Range$20.06 - $20.60
52-Week Range$12.70 - $25.70
Volume84,980 shs
Average Volume912,182 shs
Market Capitalization$1.49 billion
P/E Ratio32.38
Dividend YieldN/A
Beta1.17

About Impax Laboratories (NASDAQ:IPXL)

Impax Laboratories logoImpax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Receive IPXL News and Ratings via Email

Sign-up to receive the latest news and ratings for IPXL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:IPXL
CUSIP45256B10
Phone510-476-2000

Debt

Debt-to-Equity Ratio4.11%
Current Ratio1.96%
Quick Ratio1.52%

Price-To-Earnings

Trailing P/E Ratio32.38
Forward P/E Ratio17.23
P/E Growth0.92

Sales & Book Value

Annual Sales$775.79 million
Price / Sales1.95
Cash Flow$2.1178 per share
Price / Cash9.68
Book Value$2.53 per share
Price / Book8.10

Profitability

EPS (Most Recent Fiscal Year)$0.63
Net Income$-469,280,000.00
Net Margins-60.49%
Return on Equity10.42%
Return on Assets2.83%

Miscellaneous

Employees1,257
Outstanding Shares73,870,000

How to Become a New Pot Stock Millionaire

Impax Laboratories (NASDAQ:IPXL) Frequently Asked Questions

What is Impax Laboratories' stock symbol?

Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."

How were Impax Laboratories' earnings last quarter?

Impax Laboratories Inc (NASDAQ:IPXL) issued its quarterly earnings data on Thursday, March, 1st. The specialty pharmaceutical company reported $0.11 EPS for the quarter, missing analysts' consensus estimates of $0.12 by $0.01. The specialty pharmaceutical company earned $182.90 million during the quarter, compared to analysts' expectations of $199.13 million. Impax Laboratories had a positive return on equity of 10.42% and a negative net margin of 60.49%. The business's quarterly revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.16 earnings per share. View Impax Laboratories' Earnings History.

When is Impax Laboratories' next earnings date?

Impax Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Impax Laboratories.

What price target have analysts set for IPXL?

15 analysts have issued 1-year price objectives for Impax Laboratories' stock. Their predictions range from $16.00 to $35.00. On average, they anticipate Impax Laboratories' share price to reach $21.7333 in the next twelve months. View Analyst Ratings for Impax Laboratories.

What are Wall Street analysts saying about Impax Laboratories stock?

Here are some recent quotes from research analysts about Impax Laboratories stock:
  • 1. According to Zacks Investment Research, "Impax missed estimates for both the counts in the fourth quarter of 2017. The company faces competition in the brand product market from Parkinson’s disease and CNS disorder focused large pharmaceutical companies. Impax’s Generics segment underperformed in 2017, due to significant pricing erosion complemented by erosion in volume. However, the company’s epinephrine auto-injector sales have picked up. Meanwhile, Impax is taking steps to reduce costs and improve efficiencies, which may save an estimated $130 million by the end of 2019. The merger with Amneal Pharma is a positive for Impax as it will have a diverse pipeline with more than 300 products under review or late stage development. Shares of the company outperformed the industry in a year’s time." (3/27/2018)
  • 2. Cantor Fitzgerald analysts commented, "IPXL announced this morning that Robert Stewart will be joining the company as CEO, effective January 25, 2018." (12/15/2017)

Who are some of Impax Laboratories' key competitors?

Who are Impax Laboratories' key executives?

Impax Laboratories' management team includes the folowing people:
  • Robert L. Burr, Independent Chairman of the Board (Age 66)
  • Paul M. Bisaro, President, Chief Executive Officer, Director (Age 56)
  • Bryan M. Reasons, Chief Financial Officer, Senior Vice President - Finance (Age 49)
  • Douglas S Boothe, President - Generics Division (Age 53)
  • Michael J. Nestor, President - Impax Specialty Pharmaceutical Division (Age 64)
  • Robert A. Stewart, President of Amneal (Age 50)
  • Mark A. Schlossberg Esq., Senior Vice President, General Counsel, Corporate Secretary (Age 56)
  • Jeffrey D. Nornhold, Senior Vice President - Technical Operations (Age 51)
  • J. Kevin Buchi, Director (Age 61)
  • Janet S Vergis, Director (Age 52)

Has Impax Laboratories been receiving favorable news coverage?

News articles about IPXL stock have trended somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Impax Laboratories earned a media sentiment score of 0.04 on Accern's scale. They also gave media coverage about the specialty pharmaceutical company an impact score of 45.65 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Impax Laboratories?

Shares of IPXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Impax Laboratories' stock price today?

One share of IPXL stock can currently be purchased for approximately $20.35.

How big of a company is Impax Laboratories?

Impax Laboratories has a market capitalization of $1.49 billion and generates $775.79 million in revenue each year. The specialty pharmaceutical company earns $-469,280,000.00 in net income (profit) each year or $0.63 on an earnings per share basis. Impax Laboratories employs 1,257 workers across the globe.

How can I contact Impax Laboratories?

Impax Laboratories' mailing address is 30831 HUNTWOOD AVENUE, HAYWARD CA, 94544. The specialty pharmaceutical company can be reached via phone at 510-476-2000 or via email at [email protected]


MarketBeat Community Rating for Impax Laboratories (IPXL)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  328 (Vote Outperform)
Underperform Votes:  486 (Vote Underperform)
Total Votes:  814
MarketBeat's community ratings are surveys of what our community members think about Impax Laboratories and other stocks. Vote "Outperform" if you believe IPXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPXL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Impax Laboratories (NASDAQ:IPXL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
15 Wall Street analysts have issued ratings and price targets for Impax Laboratories in the last 12 months. Their average twelve-month price target is $21.7333, suggesting that the stock has a possible upside of 6.02%. The high price target for IPXL is $35.00 and the low price target for IPXL is $16.00. There are currently 1 sell rating, 8 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.332.272.25
Ratings Breakdown: 1 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.7333$21.4667$20.00$19.1875
Price Target Upside: 6.02% upside12.98% upside13.64% upside0.58% downside

Impax Laboratories (NASDAQ:IPXL) Consensus Price Target History

Price Target History for Impax Laboratories (NASDAQ:IPXL)

Impax Laboratories (NASDAQ:IPXL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2018BMO Capital MarketsBoost Price TargetMarket Perform -> Market Perform$18.00 -> $20.00HighView Rating Details
3/7/2018SunTrust BanksInitiated CoverageBuy -> Buy$24.00HighView Rating Details
3/2/2018Royal Bank of CanadaSet Price TargetHold$20.00LowView Rating Details
3/1/2018CowenSet Price TargetHold$21.00MediumView Rating Details
3/1/2018Canaccord GenuitySet Price TargetHold$19.00LowView Rating Details
3/1/2018Cantor FitzgeraldSet Price TargetBuy$35.00HighView Rating Details
1/2/2018Leerink SwannInitiated CoverageOutperform -> Outperform$22.00MediumView Rating Details
12/12/2017GuggenheimInitiated CoverageNeutral -> Neutral$18.00HighView Rating Details
10/30/2017UBSBoost Price TargetSell$12.00 -> $16.00N/AView Rating Details
9/28/2017Goldman SachsInitiated CoverageNeutral$20.00HighView Rating Details
9/23/2017BTIG ResearchReiterated RatingBuy$20.00 -> $27.00LowView Rating Details
9/19/2017Deutsche BankReiterated RatingBuy$23.00LowView Rating Details
9/19/2017CitigroupBoost Price TargetBuy$23.00LowView Rating Details
9/17/2017Piper JaffrayReiterated RatingHold$17.00LowView Rating Details
6/12/2017Janney Montgomery ScottReiterated RatingNeutral$21.00HighView Rating Details
3/8/2017Susquehanna BancsharesDowngradePositive -> Neutral$18.00 -> $10.00LowView Rating Details
11/14/2016WallachBeth CapitalDowngradeBuy -> Hold$30.00 -> $18.00N/AView Rating Details
11/7/2016Bank of AmericaDowngradeNeutral -> Underperform$19.00N/AView Rating Details
8/15/2016Northland SecuritiesUpgradeMarket Perform -> Outperform$30.00N/AView Rating Details
6/1/2016JPMorgan ChaseInitiated CoverageNeutral$47.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Impax Laboratories (NASDAQ:IPXL) Earnings History and Estimates Chart

Earnings by Quarter for Impax Laboratories (NASDAQ:IPXL)

Impax Laboratories (NASDAQ:IPXL) Earnings Estimates

2018 EPS Consensus Estimate: $1.17
2019 EPS Consensus Estimate: $1.50
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.15$0.27$0.21
Q2 20183$0.26$0.35$0.30
Q3 20183$0.29$0.39$0.32
Q4 20183$0.29$0.42$0.34
Q1 20191$0.31$0.31$0.31
Q2 20191$0.35$0.35$0.35
Q3 20191$0.39$0.39$0.39
Q4 20191$0.45$0.45$0.45

Impax Laboratories (NASDAQ IPXL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018$0.20N/AView Earnings Details
3/1/2018Q4 2017$0.12$0.11$199.13 million$182.90 millionViewListenView Earnings Details
11/9/2017Q3 2017$0.20$0.23$208.38 million$206.40 millionViewN/AView Earnings Details
8/9/2017Q2 2017$0.14$0.18$195.62 million$202.08 millionViewListenView Earnings Details
5/10/2017Q1 2017$0.12$0.11$193.17 million$184.40 millionViewN/AView Earnings Details
3/1/2017Q416$0.16$0.16$219.54 million$198.40 millionViewListenView Earnings Details
11/9/2016Q316$0.40$0.37$234.87 million$228.00 millionViewListenView Earnings Details
8/9/2016Q216$0.32$0.21$223.67 million$173.00 millionViewN/AView Earnings Details
5/10/2016Q116$0.39$0.43$241.84 million$226.00 millionViewListenView Earnings Details
2/22/2016Q415$0.44$0.62$223.23 million$282.10 millionViewListenView Earnings Details
11/9/2015Q315$0.39$0.40$214.69 million$221.10 millionViewN/AView Earnings Details
8/10/2015Q215$0.35$0.34$200.68 million$214.20 millionViewListenView Earnings Details
5/11/2015Q115$0.18$0.09$146.00 million$143.10 millionViewListenView Earnings Details
2/24/2015Q414$0.11$0.16$125.50 million$131.20 millionViewN/AView Earnings Details
11/4/2014Q314$0.31$0.33$148.36 million$145.63 millionViewN/AView Earnings Details
8/6/2014Q214$0.39$0.60$155.97 million$188.10 millionViewN/AView Earnings Details
5/1/2014Q114$0.13$0.24$97.80 million$118.70 millionViewN/AView Earnings Details
2/20/2014Q413$0.03($0.14)$119.01 million$100.74 millionViewN/AView Earnings Details
11/4/2013Q313($0.08)$0.25$111.83 million$115.75 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.04$0.08$120.75 million$129.63 millionViewN/AView Earnings Details
5/1/2013Q1 2013$0.21$0.37$129.12 million$148.50 millionViewN/AView Earnings Details
2/25/2013Q4 2012$0.19$0.30$127.03 million$141.10 millionViewN/AView Earnings Details
10/30/2012Q312$0.49$0.48$160.76 million$145.60 millionViewN/AView Earnings Details
7/31/2012$0.44$0.60ViewN/AView Earnings Details
5/1/2012$0.45$0.52ViewN/AView Earnings Details
2/28/2012$0.19$0.33ViewN/AView Earnings Details
11/1/2011$0.20$0.30ViewN/AView Earnings Details
8/2/2011$0.18$0.19ViewN/AView Earnings Details
5/3/2011$0.15$0.21ViewN/AView Earnings Details
2/24/2011$0.22$0.23ViewN/AView Earnings Details
11/2/2010Q3 2010$0.26$0.20ViewN/AView Earnings Details
8/3/2010Q2 2010$0.51$0.48ViewN/AView Earnings Details
5/4/2010Q1 2010$0.51$2.06ViewN/AView Earnings Details
2/25/2010Q4 2009$0.14$0.69ViewN/AView Earnings Details
11/3/2009Q3 2009$0.04$0.11ViewN/AView Earnings Details
8/4/2009Q2 2009$0.03$0.05ViewN/AView Earnings Details
5/5/2009Q1 2009($0.07)$0.05ViewN/AView Earnings Details
2/26/2009Q4 2008$0.15ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Impax Laboratories (NASDAQ:IPXL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Impax Laboratories (NASDAQ IPXL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.20%
Institutional Ownership Percentage: 90.40%
Insider Trading History for Impax Laboratories (NASDAQ:IPXL)
Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)

Impax Laboratories (NASDAQ IPXL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/31/2017Michael NestorInsiderSell1,130$15.00$16,950.00106,943View SEC Filing  
5/17/2017Michael NestorInsiderSell857$16.48$14,123.36108,073View SEC Filing  
5/12/2017Michael NestorInsiderSell700$17.11$11,977.00115,168View SEC Filing  
8/15/2016Leslie Z BenetDirectorSell10,092$22.81$230,198.5240,225View SEC Filing  
9/11/2015Mark A SchlossbergSVPSell7,457$43.30$322,888.1073,588View SEC Filing  
9/10/2015Michael NestorInsiderSell5,000$43.56$217,800.00111,833View SEC Filing  
8/31/2015Michael MarkbreiterDirectorSell28,000$41.70$1,167,600.008,200View SEC Filing  
8/27/2015Mark A SchlossbergSVPSell4,649$43.41$201,813.0981,045View SEC Filing  
8/27/2015Peter R TerreriDirectorSell4,833$43.93$212,313.6939,787View SEC Filing  
8/26/2015Michael MarkbreiterDirectorSell19,399$42.24$819,413.768,200View SEC Filing  
6/6/2014Larry HsuDirectorSell100,000$28.38$2,838,000.00View SEC Filing  
5/27/2014Peter R TerreriDirectorSell3,000$28.00$84,000.00View SEC Filing  
5/22/2014Larry HsuDirectorSell50,000$27.22$1,361,000.00409,568View SEC Filing  
5/21/2014Larry HsuDirectorSell3,800$26.53$100,814.00459,568View SEC Filing  
5/16/2014Nigel FlemingDirectorSell1,900$25.72$48,868.0011,266View SEC Filing  
5/12/2014Nigel FlemingDirectorSell1,333$26.58$35,431.148,366View SEC Filing  
5/8/2014Michael MarkbreiterDirectorSell12,500$26.44$330,500.009,699View SEC Filing  
5/6/2014Larry HsuDirectorSell219,386$26.28$5,765,464.08458,568View SEC Filing  
3/11/2014Michael MarkbreiterDirectorSell4,000$27.54$110,160.009,699View SEC Filing  
1/8/2014Robert BurrDirectorSell1,500$24.31$36,465.0043,825View SEC Filing  
11/13/2013Robert BurrDirectorSell1,500$22.98$34,470.0046,825View SEC Filing  
10/9/2013Robert BurrDirectorSell1,500$20.10$30,150.0048,325View SEC Filing  
9/11/2013Robert BurrDirectorSell1,500$20.87$31,305.0049,825View SEC Filing  
8/14/2013Robert BurrDirectorSell1,500$21.15$31,725.0051,325View SEC Filing  
7/10/2013Robert L BurrDirectorSell1,500$20.26$30,390.00View SEC Filing  
6/12/2013Robert L BurrDirectorSell1,500$18.80$28,200.00View SEC Filing  
5/8/2013Robert L BurrDirectorSell1,500$16.35$24,525.00View SEC Filing  
5/1/2013Peter R TerreriDirectorSell3,450$17.39$59,995.50View SEC Filing  
3/12/2013Larry HsuCEOBuy7,000$16.88$118,160.00View SEC Filing  
3/12/2013Mark A SchlossbergSVPBuy1,000$16.73$16,730.00View SEC Filing  
2/13/2013Robert L BurrDirectorSell1,500$19.82$29,730.00View SEC Filing  
11/14/2012Robert L BurrDirectorSell1,500$19.86$29,790.00View SEC Filing  
8/20/2012Nigel FlemingDirectorSell6,000$23.99$143,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Impax Laboratories (NASDAQ IPXL) News Headlines

Source:
DateHeadline
Impax Laboratories (IPXL) Upgraded at BidaskClubImpax Laboratories (IPXL) Upgraded at BidaskClub
www.americanbankingnews.com - April 19 at 9:04 AM
Impax Laboratories Inc to Post Q2 2018 Earnings of $0.26 Per Share, Piper Jaffray Forecasts (IPXL)Impax Laboratories Inc to Post Q2 2018 Earnings of $0.26 Per Share, Piper Jaffray Forecasts (IPXL)
www.americanbankingnews.com - April 19 at 6:26 AM
Zacks: Brokerages Expect Impax Laboratories Inc (IPXL) Will Announce Quarterly Sales of $183.35 MillionZacks: Brokerages Expect Impax Laboratories Inc (IPXL) Will Announce Quarterly Sales of $183.35 Million
www.americanbankingnews.com - April 19 at 4:26 AM
Leerink Swann Analysts Raise Earnings Estimates for Impax Laboratories Inc (IPXL)Leerink Swann Analysts Raise Earnings Estimates for Impax Laboratories Inc (IPXL)
www.americanbankingnews.com - April 18 at 8:56 AM
Impax Laboratories (IPXL) Upgraded to "Neutral" at Piper JaffrayImpax Laboratories (IPXL) Upgraded to "Neutral" at Piper Jaffray
www.americanbankingnews.com - April 17 at 7:00 PM
Q1 2018 EPS Estimates for Impax Laboratories Inc Cut by Leerink Swann (IPXL)Q1 2018 EPS Estimates for Impax Laboratories Inc Cut by Leerink Swann (IPXL)
www.americanbankingnews.com - April 17 at 6:51 AM
Zacks: Analysts Expect Impax Laboratories Inc (IPXL) to Post $0.17 EPSZacks: Analysts Expect Impax Laboratories Inc (IPXL) to Post $0.17 EPS
www.americanbankingnews.com - April 17 at 5:15 AM
BMO Capital Markets Increases Impax Laboratories (IPXL) Price Target to $20.00BMO Capital Markets Increases Impax Laboratories (IPXL) Price Target to $20.00
www.americanbankingnews.com - April 16 at 8:45 AM
Impax Laboratories (IPXL) Receives New Coverage from Analysts at Canaccord GenuityImpax Laboratories (IPXL) Receives New Coverage from Analysts at Canaccord Genuity
www.americanbankingnews.com - April 15 at 9:45 AM
Edited Transcript of IPXL presentation 6-Mar-17 4:35pm GMTEdited Transcript of IPXL presentation 6-Mar-17 4:35pm GMT
finance.yahoo.com - April 12 at 5:40 PM
Impax Laboratories (IPXL) Stock Rating Lowered by BidaskClubImpax Laboratories (IPXL) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 12 at 10:23 AM
Impax Laboratories (IPXL) Given a $20.00 Price Target at CowenImpax Laboratories (IPXL) Given a $20.00 Price Target at Cowen
www.americanbankingnews.com - April 11 at 1:21 PM
Canaccord Genuity Analysts Give Impax Laboratories (IPXL) a $19.00 Price TargetCanaccord Genuity Analysts Give Impax Laboratories (IPXL) a $19.00 Price Target
www.americanbankingnews.com - April 11 at 12:43 AM
Impax Laboratories (IPXL) PT Set at $17.00 by Piper JaffrayImpax Laboratories (IPXL) PT Set at $17.00 by Piper Jaffray
www.americanbankingnews.com - April 10 at 10:31 PM
Blog Exposure - Impax Launched a Generic Version of Estrace(R) CreamBlog Exposure - Impax Launched a Generic Version of Estrace(R) Cream
finance.yahoo.com - April 10 at 8:24 AM
Impax Laboratories (IPXL) Upgraded to Buy at Zacks Investment ResearchImpax Laboratories (IPXL) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - April 7 at 9:13 AM
Impax Laboratories (IPXL) Given a $25.00 Price Target at Cantor FitzgeraldImpax Laboratories (IPXL) Given a $25.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - April 6 at 10:54 PM
Impax launches a generic version of Estrace creamImpax launches a generic version of Estrace cream
seekingalpha.com - April 6 at 8:24 AM
Impax Launches a Generic Version of Estrace® Cream (estradiol vaginal cream, USP, 0.01%)Impax Launches a Generic Version of Estrace® Cream (estradiol vaginal cream, USP, 0.01%)
finance.yahoo.com - April 6 at 8:24 AM
Impax Laboratories Inc (IPXL) Given Average Recommendation of "Hold" by BrokeragesImpax Laboratories Inc (IPXL) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 4 at 9:51 AM
Impax Laboratories (IPXL) Downgraded by ValuEngineImpax Laboratories (IPXL) Downgraded by ValuEngine
www.americanbankingnews.com - April 3 at 1:22 PM
Blog Exposure - Assembly Biosciences to Present ABI-H0731 Phase-1b Interim Data at The International Liver Congress(TM)Blog Exposure - Assembly Biosciences to Present ABI-H0731 Phase-1b Interim Data at The International Liver Congress(TM)
finance.yahoo.com - April 2 at 8:36 AM
Why Is Impax Laboratories (IPXL) Down 1% Since Its Last Earnings Report?Why Is Impax Laboratories (IPXL) Down 1% Since Its Last Earnings Report?
finance.yahoo.com - April 2 at 8:36 AM
$184.90 Million in Sales Expected for Impax Laboratories Inc (IPXL) This Quarter$184.90 Million in Sales Expected for Impax Laboratories Inc (IPXL) This Quarter
www.americanbankingnews.com - April 2 at 4:00 AM
Zacks: Analysts Anticipate Impax Laboratories Inc (IPXL) Will Announce Earnings of $0.17 Per ShareZacks: Analysts Anticipate Impax Laboratories Inc (IPXL) Will Announce Earnings of $0.17 Per Share
www.americanbankingnews.com - March 31 at 9:24 AM
Impax reaches $20 mln deal to end trial over generic drugs delayImpax reaches $20 mln deal to end trial over generic drug's delay
finance.yahoo.com - March 29 at 5:32 PM
Impax Laboratories (IPXL) Approve Proposed Business Combination with AmnealImpax Laboratories (IPXL) Approve Proposed Business Combination with Amneal
www.streetinsider.com - March 28 at 8:25 AM
Impax Shareholders Approve Proposed Business Combination with AmnealImpax Shareholders Approve Proposed Business Combination with Amneal
finance.yahoo.com - March 28 at 8:25 AM
Impax Laboratories (IPXL) Downgraded to Sell at Zacks Investment ResearchImpax Laboratories (IPXL) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - March 27 at 1:51 PM
Impax Laboratories (IPXL) Lowered to "Sell" at BidaskClubImpax Laboratories (IPXL) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - March 24 at 1:56 PM
Teva’s Recent Launch of Generic Solodyn: What You Need to KnowTeva’s Recent Launch of Generic Solodyn: What You Need to Know
finance.yahoo.com - March 22 at 5:38 PM
Impax Laboratories (IPXL) Stock Rating Lowered by Zacks Investment ResearchImpax Laboratories (IPXL) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 19 at 1:45 PM
Impax Laboratories (IPXL) Lifted to "Buy" at Zacks Investment ResearchImpax Laboratories (IPXL) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 16 at 3:06 PM
Impax Laboratories Inc (IPXL) Expected to Announce Quarterly Sales of $184.90 MillionImpax Laboratories Inc (IPXL) Expected to Announce Quarterly Sales of $184.90 Million
www.americanbankingnews.com - March 16 at 7:02 AM
Amneal Gains FDA Approval for Erythromycin Tablets USP (IPXL)Amneal Gains FDA Approval for Erythromycin Tablets USP (IPXL)
www.streetinsider.com - March 14 at 7:09 PM
Impax Laboratories (IPXL) Rating Increased to Hold at BidaskClubImpax Laboratories (IPXL) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - March 14 at 6:38 PM
Amneal Gains Approval for Erythromycin Tablets USPAmneal Gains Approval for Erythromycin Tablets USP
finance.yahoo.com - March 14 at 8:29 AM
$0.17 Earnings Per Share Expected for Impax Laboratories Inc (IPXL) This Quarter$0.17 Earnings Per Share Expected for Impax Laboratories Inc (IPXL) This Quarter
www.americanbankingnews.com - March 14 at 5:17 AM
Impax faces U.S. antitrust trial over generic acne drugs delayImpax faces U.S. antitrust trial over generic acne drug's delay
finance.yahoo.com - March 12 at 6:41 PM
Impax broke U.S. antitrust law by delaying generic drug, jury toldImpax broke U.S. antitrust law by delaying generic drug, jury told
finance.yahoo.com - March 12 at 6:41 PM
Brokers Issue Forecasts for Impax Laboratories Incs Q1 2018 Earnings (IPXL)Brokers Issue Forecasts for Impax Laboratories Inc's Q1 2018 Earnings (IPXL)
www.americanbankingnews.com - March 12 at 2:12 AM
Impax Laboratories Inc (IPXL) Receives Consensus Rating of "Hold" from BrokeragesImpax Laboratories Inc (IPXL) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 10 at 9:45 AM
Analyzing Aegerion Pharmaceuticals (AEGR) and Impax Laboratories (IPXL)Analyzing Aegerion Pharmaceuticals (AEGR) and Impax Laboratories (IPXL)
www.americanbankingnews.com - March 8 at 7:13 PM
SunTrust Banks Initiates Coverage on Impax Laboratories (IPXL)SunTrust Banks Initiates Coverage on Impax Laboratories (IPXL)
www.americanbankingnews.com - March 7 at 9:06 PM
Amneal Pharmaceuticals and Impax Laboratories to Present at the Barclays Global Healthcare ConferenceAmneal Pharmaceuticals and Impax Laboratories to Present at the Barclays Global Healthcare Conference
finance.yahoo.com - March 7 at 6:37 PM
FY2018 EPS Estimates for Impax Laboratories Inc Boosted by Analyst (IPXL)FY2018 EPS Estimates for Impax Laboratories Inc Boosted by Analyst (IPXL)
www.americanbankingnews.com - March 7 at 11:51 AM
Amneal Pharmaceuticals, LLC -- Moodys rates Amneals new term loan B1; outlook revised to positiveAmneal Pharmaceuticals, LLC -- Moody's rates Amneal's new term loan B1; outlook revised to positive
finance.yahoo.com - March 6 at 5:42 PM
Impax Laboratories Inc to Post Q4 2018 Earnings of $0.41 Per Share, Leerink Swann Forecasts (IPXL)Impax Laboratories Inc to Post Q4 2018 Earnings of $0.41 Per Share, Leerink Swann Forecasts (IPXL)
www.americanbankingnews.com - March 5 at 7:26 AM
Impax Laboratories Inc (IPXL) Shares Bought by WINTON GROUP LtdImpax Laboratories Inc (IPXL) Shares Bought by WINTON GROUP Ltd
www.americanbankingnews.com - March 4 at 2:27 PM
Impax Laboratories (IPXL) PT Set at $21.00 by CowenImpax Laboratories (IPXL) PT Set at $21.00 by Cowen
www.americanbankingnews.com - March 3 at 5:38 PM

SEC Filings

Impax Laboratories (NASDAQ:IPXL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Impax Laboratories (NASDAQ:IPXL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Impax Laboratories (NASDAQ IPXL) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.